BriaCell Therapeutics (BCTX) said Thursday that its board has approved a share consolidation on the basis of one new share for every 10 currently outstanding shares to ensure continued compliance with the listing requirements of The Nasdaq Capital Market.
The consolidation is subject to approval by the Nasdaq and the Toronto Stock Exchange, and is expected to become effective on Aug. 25, the company said.
Price: 0.66, Change: -0.03, Percent Change: -4.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments